AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05021978
Drug: Part B: 120 mg PRAX-944
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral treatment with titration
Trial: NCT05021978
Drug: Part B: 120 mg PRAX-944 and Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily oral treatment with titration followed by placebo
Trial: NCT01048619
Drug: ON 01910.Na
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Part I, the bioavailability and tolerability of ON 01910.Na as single, oral, escalating doses in a fasting state (defined as no less than 30 min before next meal) is studied. Three patients get 70mg dose the 1st week. In the absence of drug-related grade 2 toxicity or higher, doses will escalate in each patient weekly (wk) to 140mg (wk 2), 280mg (wk 3), 560mg (wk 4) and 700mg (wk 5). At end of Part I all patients will be eligible for Part II. Part II proceeds if drug is measured in plasma and DLT not observed at 70mg dose in Part I. The maximum tolerated dose of oral ON 01910.Na administered in a fasting state (defined as no less than 30 min before next meal) twice a day for 14 days will be determined following an adaptive design at doses between 70 and 700mg.
Trial: NCT03201601
Drug: Myoinositol
RxNorm normalized name: mesoinositol hexanicotinate
DrugBank: Inositol nicotinate (DB08949)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each participant will consume 2 capsules daily of each treatment, in the morning and at night without any restriction in the diet nor in their habits of life. The treatment will last 12 weeks.
Trial: NCT04056325
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy, oral administration, single dose, matching number of tablets
Trial: NCT04444726
Drug: Topical medical treatment (Betamethasone dipropionate 0.05%  diprolene  )
RxNorm normalized name: Hongo Killer Treatment Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: thin film of the cream is being applied to the affected areas for 2 times per day.
Trial: NCT01128634
Drug: GSK573719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13 days dosing with GSK573719, once daily dosing from day 1 to 13, concurrent dosing with verapamil from day 9 to 13.
Trial: NCT01128634
Drug: GW573719/GW573719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13 days dosing with GSK573719/GW573719, once daily dosing from day 1 to 13, concurrent dosing with verapamil from day 9 to 13.
Trial: NCT02387853
Drug: LEO 90100
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02686749
Drug: FDA approved anti arrhythmic drug
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti arrhythmic drug medical treatment will be based on treating physicians discretion following standard clinical guidelines
Trial: NCT01408173
Drug: NPC-11 for intravenous or oral administration.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPC-11, Each vial (3mL) contains 60 mg caffeine citrate (equivalent to 30mg caffeine).
Trial: NCT01394796
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No active treatment is given.
Trial: NCT03279744
Drug: Radion™-pdt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Radion™-pdt will be applied topically to the lesion. The Radion™-pdt applied dosage is about 0.1 mL/cm\^2 and properly cover the entire lesion.
Trial: NCT01577992
Drug: Levodopa test
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Each patients with PD and MSA will be evaluated in two conditions : OFF (without dopaminergic treatment since 12h) and ON condition (after a L-DOPA dose. This dose will be 150% of the DOPA morning dose. The healthy volunteers will be evaluated in only one condition (without L-DOPA administration)
Trial: NCT03516188
Drug: Alginate-antacid group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be given 10 mL of alginate-antacid preparation (Gaviscon-Advance®, Reckitt-Benckiser, United Kingdom)
Trial: NCT03516188
Drug: Non antacid alginate group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be given 4 mL of magnesium tri-silicate which has equivalent strength and component with Gaviscon-Advance® except it is alginate-free.
Trial: NCT03873116
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules administered orally once daily
Trial: NCT00240513
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg capsules OD for 3 months
Trial: NCT00240513
Drug: Minocycline plus tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg OD Minocycline for 12 weeks plus OD Topical tretinoin 0.01% for 12 weeks Followed by topical tretinoin 0.01% OD for 12 weeks alone
Trial: NCT00003475
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adults with a primary malignant brain tumor that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT00597220
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00577304
Drug: Topical AmphiMatrix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.
Trial: NCT00658359
Drug: CP-690,550
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CP-690,550 tablets dosed BID Months 12-72
Trial: NCT02249546
Drug: PPI-amoxicillin-clarithromycin
RxNorm normalized name: lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triple therapy
Trial: NCT01085331
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be administered with placebo orally once daily on days 1-5, 8-12, 15-19, and 22-26 of a 28 day cycle.
Trial: NCT01197846
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00132665
Drug: B: CBDCA and Radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: B: CBDCA and Radiotherapy
Trial: NCT02910531
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Already mentioned in arm/group descriptions.
Trial: NCT03636152
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo for the control group.
Trial: NCT00281931
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00472576
Drug: MK-0657
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily double-blind administration of the NR2B antagonist MK-0657 (4-8 mg/day)
Trial: NCT00472576
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily double-blind administration of placebo
Trial: NCT01046487
Drug: Imatinib mesylate, Cyclophosphamide (Dosing level 1 )
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYCLE 1 (42 days):~* Day 1 to 14 Imatinib mesylate : 400 mg/day, per os~* Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 400 mg/day, per os~NEXT CYCLE (28 days):~Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 400 mg/day, per os
Trial: NCT01046487
Drug: Imatinib mesylate, Cyclophosphamide (Dosing level 2)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYCLE 1 (42 days):~* Day 1 to 14 Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening) per os~* Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening) per os~NEXT CYCLE (28 days):~Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening)per os
Trial: NCT04502862
Drug: SAR231893
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
Trial: NCT04502862
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
Trial: NCT01046487
Drug: Imatinib mesylate, Cyclophosphamide (Dosing level 3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CYCLE 1 (42 days):~* Day 1 to 14 Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening) per os~* Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening) per os~NEXT CYCLE (28 days):~Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening)per os
Trial: NCT01716221
Drug: Placebo & Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01670552
Drug: Naproxen + Esomeprazole
RxNorm normalized name: esomeprazole / naproxen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet each 12 hours for 14 days plus 1 tablet each 12 hours for 14 days of the Nimesulide + Pantoprazole placebo.
Trial: NCT01336647
Drug: Group A - Low-Dose Ha44 0.37% w/w
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose Ha44 Gel applied to scalp and hair for 10 minutes
Trial: NCT01336647
Drug: Group B - High Dose Ha44 Gel 0.74% w/w
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Dose Ha44 Gel applied to scalp and hair for 10 minutes
Trial: NCT01336647
Drug: Group C - Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo- vehicle Ha44 Gel without active ingredient applied to scalp and hair for 10 minutes
Trial: NCT02288741
Drug: Tumor-reduction chemotherapy and stem cell mobilization
RxNorm normalized name: human breast tumor cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ifosfamide (day 1-3: 1.900mg/m² iv), epirubicin (day 1: 75 mg/m² iv), etoposide (day 1-3: 120 mg/m² iv) and G-CSF (day 5 until end of apheresis: 5µg/kg sc)
Trial: NCT02288741
Drug: Tandem high-dose chemotherapy (melphalan)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two cycles of high-dose melphalan (day -3 and day -2: 70mg/m²)
Trial: NCT01328132
Drug: 25% albumin
RxNorm normalized name: Flexbumin 25% Albumin (Human) Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of 25% albumin will be given in addition to the standard of care every 8 hours for 24 hours
Trial: NCT02132026
Drug: Alendronic Acid
RxNorm normalized name: Alendronic Acid
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02132026
Drug: Alendronic Acid Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert Capsule containing lactose monohydrate manufactured and labelled by Investigational Supplies Group (ISG) University of Edinburgh.
Trial: NCT01497496
Drug: High Dose Methylprednisolone (HDMP)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1000 mg/m\^2 on Cycle 1: Day 1, 8, 15, 22; Cycle 2: Day 1, 15; Cycle 3: Day 1, 15
Trial: NCT02792686
Drug: ABX464
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Administration
Trial: NCT01217229
Drug: PLX3397
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules administered once or twice daily, continuous dosing. Subjects will begin with 900 mg/day, but should safety data allow in our PLX108-01 study, subject may dose at 1200 mg/day.
Trial: NCT00953849
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib (400 mg twice daily)
Trial: NCT03146416
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT02952820
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00335595
Drug: XELOXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XELOXA Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 One cycle every 3 weeks
Trial: NCT00335595
Drug: XELOXA-A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XELOXA-A Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 during 6 cycles followed by Bevacizumab until disease progression or premature drop out of study.~One cycle every 3 weeks
Trial: NCT02319018
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02319018
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01297829
Drug: Intravenous Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg IV ibuprofen 30 minutes preoperatively
Trial: NCT01599637
Drug: IGE025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.
Trial: NCT01599637
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.
Trial: NCT04139018
Drug: Placebo Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel is prepared with poloxamers and no active ingredients.
Trial: NCT00411684
Drug: CDB-2914
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02873416
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin：60mg/m2，Gemcitabine：1g/ m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
Trial: NCT03192735
Drug: ApatinibMesylateTablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will be given ApatinibMesylateTablets 500mg/per day, from day1-day 21,per os; Oxaliplatin for Injection 130mg/m2 /per day，ivgtt，in day1; Gimeracil and Oteracil Porassium Capsules twice times a day,from day1-day 14,per os,and the dosage according body surface area:\<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; \>1.5m2, 60mg every time.A course of treatment need 21days. Every subject need 2-5 courses accrding to tumor assessment by clinician. The last course stop ApatinibMesylateTablets.
Trial: NCT01040910
Drug: smoking cigarettes with placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: smoking cigarettes with cannabis that was chemically treated so that most active ingredients were removed
Trial: NCT00036985
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00036985
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04171843
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is used for lymphodepletion.
Trial: NCT02010359
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill
Trial: NCT04731740
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigators' choice
Trial: NCT03123627
Drug: New profilaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary endpoint: incidence of CMV disease at 12 months after transplantation. Study the predictive value of the assay of CD8 + T cell immunity specific for defined CMV-patients in which they can stop prophylaxis. The definition of CMV disease was based on those recommended by the American Society of Trasnplantation for use in clinical trials (Humar A. Am J Transplant 2006; 6:262-74) criteria.
Trial: NCT02226380
Drug: mFOLFOX6 regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxaliplatin 85 mg/m2 and folinic acid 400 mg/m2 are administered intravenously for 2 hours on day 1 following by 5-FU at 2,400 mg/m2 by continuous infusion for 46hours every 2 weeks for 3 cycles before performing surgery
Trial: NCT02157883
Drug: AZD9291
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD9291 tablets: Part A 80mg od, days 1 and 10 only. Part B 80mg od for 12 months.
Trial: NCT01767090
Drug: ASP1707
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01767090
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01789476
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered using same dosing algorithm as the active arm
Trial: NCT00967070
Drug: Placebo Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
Trial: NCT04123743
Drug: Trigonella foenum-graceum extract topical cream
RxNorm normalized name: Trigonella foenum-graecum whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical cream containing Trigonella foenum-graceum extract
Trial: NCT01016249
Drug: Treatment 1. (5% Hypertonic saline + Epinephrine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulization of 4ml 5% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
Trial: NCT01016249
Drug: Treatment 3. (3% Hypertonic saline + Epinephrine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulization of 4ml 3% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
Trial: NCT01016249
Drug: Treatment 2. (Normal saline + Epinephrine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulization of 4ml 0.9% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
Trial: NCT02713893
Drug: Placebo intravaginal cream
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01741558
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The treatment group will receive a bolus dose of 0.05 mg/kg of methotrexate before primary angioplasty followed by 0.05 mg/kg per hour for 6 hours
Trial: NCT02434666
Drug: CPC-201
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01395420
Drug: CAZ104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Infusion
Trial: NCT03339999
Drug: AGN-242428
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN-242428 administered as an oral capsule(s) once daily.
Trial: NCT03339999
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered as an oral capsule(s) once daily.
Trial: NCT01396811
Drug: 33525
RxNorm normalized name: POUCH,CLOSED,KARAYA SEAL H#3325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily for 14 days
Trial: NCT01396811
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily for 14 days
Trial: NCT04262843
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02218034
Drug: AGN-190168 Formulation 1
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
Trial: NCT02218034
Drug: AGN-190168 Formulation 2
RxNorm normalized name: VITEX AGNUS-CASTUS WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
Trial: NCT01582269
Drug: LY2157299 monohydrate
RxNorm normalized name: Lactose Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered as tablets
Trial: NCT01582269
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally administered as tablets
Trial: NCT00131027
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00131027
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00131027
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 g/sqm (high dose)
Trial: NCT00131027
Drug: Mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00131027
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00131027
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.5 g/sqm (intermediate dose)
Trial: NCT03287089
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT03173248
Drug: AG-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally
Trial: NCT03173248
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally
Trial: NCT02140996
Drug: Ad-sig-hMUC-1/ecdCD40L vector vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01388946
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no